CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.04.15	Cellectis Opens Labs and Offices in Manhattan, New York (Businesswire)
25.03.15	Cellectis Prices Initial Public Offering of American Depositary Shares (Businesswire)
04.03.15	Cellectis: 2014 Financial Results (Businesswire)
17.02.15	Cellectis SA Shareholders General Meeting of February 16, 2015 (Businesswire)
13.01.15	Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma (Businesswire)
08.01.15	Cellectis Plans to Conduct Registered Initial Public Offering in the U.S. (Businesswire)
06.01.15	Cellectis Announces the Issuance by the USPTO of a Patent Covering a Seminal Nuclease-Based "gene editing” Method (Businesswire)
18.12.14	Cellectis Plant Sciences and Two Blades Foundation Announce the Execution of a Cross-License Agreement on TAL Effector Nuclease Technologies (Businesswire)
24.11.14	Cellectis Announces Upcoming Presentations at the 56th Annual Meeting of the American Society of Hematology (ASH) (Businesswire)
12.11.14	Cellectis Received Proceeds of €13 Million Through the Exercise of Warrants (Businesswire)
04.11.14	Cellectis: TALENTM Technology: Grant of EP 2 510 096 by the European Patent Office (Businesswire)
30.10.14	Cellectis: Event Report: Individual Shareholders’ Meeting Held on October 23, 2014 (Businesswire)
30.09.14	Cellectis: First-Half 2014 Financial Results (Businesswire)
29.09.14	Cellectis Plant Sciences Launches Its New Website (Businesswire)
23.09.14	Cellectis : Individual Shareholder Meeting (Businesswire)
16.09.14	Event report: Cellectis R&D/ Analyst Day (Businesswire)
04.09.14	Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc. (Businesswire)
02.09.14	Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology (Businesswire)
31.07.14	Pfizer’s Stake in Cellectis’ Capital is Welcomed by Its Shareholders (Businesswire)
29.07.14	Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc. (Businesswire)
30.06.14	Cellectis SA Combined General Shareholders’ Meeting of June 27, 2014 (Businesswire)
25.06.14	Cellectis R&D / Analyst Day (Businesswire)
23.06.14	Cellectis’ UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA (Businesswire)
19.06.14	Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014 (Businesswire)
18.06.14	Pfizer and Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration (Businesswire)
10.06.14	Cellectis to Present New Data Update on Its Allogeneic CAR T Cell Therapeutics at the 19th Congress of the European Hematology Association (EHA) (Businesswire)
09.06.14	Cellectis enters into an agreement with CELLforCURE for the cGMP manufacturing of allogeneic CART cells (Businesswire)
05.06.14	Cellectis and Accelera (Nerviano Medical Sciences Group) Sign an Agreement to Complete Preclinical Studies of Cellectis’ Lead Product Candidate UCART19 (Businesswire)
05.06.14	Cellectis and Thermo Fisher Scientific Enter Into Agreements on TALEN™, a Leading Gene Editing Technology (Businesswire)
29.05.14	Cellectis plant sciences reports improvement of oil content in algae (Businesswire)
23.05.14	Cellectis Plant Sciences Reports Generation of High Oleic Soybean in Journal of Plant Biotechnology (Businesswire)
19.05.14	TAL-effector Nuclease: The USPTO Issues a Fourth Patent Licensed to Cellectis (Businesswire)
11.04.14	Cellectis: 2013 financial results (Businesswire)
31.03.14	Cellectis Announces the Closing of €20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors (Businesswire)
25.03.14	Cellectis Receives €20.5 M in Commitments in Private Placement from U.S. Biotechnology Specialist Institutional Investors (Businesswire)
17.02.14	Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors (Businesswire)
05.02.14	US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases (Businesswire)
04.02.14	Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models (Businesswire)
30.01.14	Precision BioSciences and Cellectis SA Announce Cross-License and Settlement Agreement for Gene Editing Technology (Businesswire)
30.01.14	Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing (Businesswire)
17.01.14	Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays (Businesswire)
09.01.14	Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program (Businesswire)
07.01.14	Cellectis Reorganizes Its Tools and Services Business Line, in Partnership with Caisse Des Dépôts, by Contributing Ectycell’s Shares to Cellectis Bioresearch (Businesswire)
05.12.13	Cellectis announces an acceleration of its strategic refocusing on therapeutics and agrobusiness (Businesswire)
26.09.13	Cellectis announces first-half 2013 financial results (Businesswire)
23.09.13	Cellectis Bioresearch Launches Compact TALENTM the Next Generation of TAL Effector Nucleases (Businesswire)
08.07.13	Scéil(TM) : A New Offering for the General Public to Turn Adult Cells into Stem Cells and Store Them (Businesswire)
04.07.13	Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia (Businesswire)
18.12.12	Cellectis: An Innovative Anti-cancer Approach (Businesswire)
12.11.12	2012 Nobel laureate in medicine Shinya Yamanaka reaffirms commitment to CiRA-Cellectis partnership (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten